Arrowhead Pharmaceuticals’ (ARWR) Buy Rating Reiterated at HC Wainwright

Arrowhead Pharmaceuticals (NASDAQ:ARWR)‘s stock had its “buy” rating reissued by HC Wainwright in a research report issued to clients and investors on Thursday, Benzinga reports. They presently have a $120.00 price objective on the biotechnology company’s stock. HC Wainwright’s target price would suggest a potential upside of 105.13% from the stock’s current price.

A number of other research analysts have also issued reports on ARWR. B. Riley Financial boosted their target price on shares of Arrowhead Pharmaceuticals from $101.00 to $123.00 and gave the company a “buy” rating in a research note on Thursday, July 30th. Piper Sandler reissued an “overweight” rating and set a $126.00 target price (up from $110.00) on shares of Arrowhead Pharmaceuticals in a research note on Thursday, July 23rd. Wall Street Zen raised shares of Arrowhead Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, June 27th. Morgan Stanley boosted their target price on shares of Arrowhead Pharmaceuticals from $100.00 to $120.00 and gave the company an “overweight” rating in a research note on Thursday, July 23rd. Finally, Chardan Capital reissued a “buy” rating and set a $115.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Monday, August 31st. Eleven equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $99.07.

Arrowhead Pharmaceuticals Stock Performance

Shares of NASDAQ:ARWR traded up $0.13 during trading on Thursday, reaching $58.50. 2,009,461 shares of the company’s stock traded hands, compared to its average volume of 2,292,497. The company has a debt-to-equity ratio of 1.77, a current ratio of 5.90 and a quick ratio of 5.90. Arrowhead Pharmaceuticals has a 12 month low of $36.57 and a 12 month high of $95.49. The company has a 50 day moving average of $76.71 and a 200-day moving average of $75.99. The stock has a market capitalization of $8.24 billion, a P/E ratio of -26.00 and a beta of 1.29.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its quarterly earnings data on Tuesday, August 4th. The biotechnology company reported ($1.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.13). Arrowhead Pharmaceuticals had a negative net margin of 47.79% and a negative return on equity of 60.06%. The business had revenue of $75.25 million for the quarter, compared to the consensus estimate of $44.17 million. During the same period in the prior year, the company earned ($1.26) EPS. Arrowhead Pharmaceuticals’s quarterly revenue was up 171.0% on a year-over-year basis. On average, equities analysts expect that Arrowhead Pharmaceuticals will post -3.62 EPS for the current year.

Insider Transactions at Arrowhead Pharmaceuticals

In other Arrowhead Pharmaceuticals news, Director Adeoye Olukotun sold 2,000 shares of the business’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $86.96, for a total transaction of $173,920.00. Following the completion of the transaction, the director directly owned 31,600 shares of the company’s stock, valued at $2,747,936. The trade was a 5.95% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Michael Perry sold 11,600 shares of the business’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $87.30, for a total transaction of $1,012,680.00. Following the transaction, the director directly owned 111,459 shares of the company’s stock, valued at $9,730,370.70. The trade was a 9.43% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders own 3.60% of the company’s stock.

Institutional Trading of Arrowhead Pharmaceuticals

A number of institutional investors have recently made changes to their positions in ARWR. Optiver Holding B.V. lifted its stake in shares of Arrowhead Pharmaceuticals by 83.8% in the 1st quarter. Optiver Holding B.V. now owns 408 shares of the biotechnology company’s stock worth $26,000 after acquiring an additional 186 shares during the period. Versant Capital Management Inc lifted its stake in shares of Arrowhead Pharmaceuticals by 285.1% in the 2nd quarter. Versant Capital Management Inc now owns 335 shares of the biotechnology company’s stock worth $27,000 after acquiring an additional 248 shares during the period. Carolina Wealth Advisors LLC lifted its stake in shares of Arrowhead Pharmaceuticals by 80.6% in the 2nd quarter. Carolina Wealth Advisors LLC now owns 345 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 154 shares during the period. Persistent Asset Partners Ltd acquired a new stake in Arrowhead Pharmaceuticals in the second quarter worth approximately $39,000. Finally, First Horizon Corp lifted its position in Arrowhead Pharmaceuticals by 36.3% in the first quarter. First Horizon Corp now owns 654 shares of the biotechnology company’s stock worth $41,000 after purchasing an additional 174 shares during the period. 62.61% of the stock is owned by institutional investors and hedge funds.

Arrowhead Pharmaceuticals News Summary

Here are the key news stories impacting Arrowhead Pharmaceuticals this week:

• Positive Sentiment: Arrowhead reported Phase 1/2a interim data showing deep and durable tau reductions of up to 73% in healthy volunteers. The results represent an early clinical validation that the company’s RNAi technology can deliver siRNA across the blood-brain barrier, a major challenge in developing neurological treatments. Arrowhead ARO-MAPT interim Phase 1/2a clinical data
• Positive Sentiment: The ARO-MAPT announcement prompted favorable coverage, with investors viewing the data as potentially establishing a new platform for treating Alzheimer’s and other tauopathies. Arrowhead reports positive ARO-MAPT data
• Positive Sentiment: UBS initiated coverage with a Buy rating and a $109 price target. Chardan Capital reaffirmed its Buy rating with a $115 target, while HC Wainwright maintained its Buy rating and raised or reiterated a $120 target. These targets imply substantial upside and reinforce the bullish view among analysts.
• Neutral Sentiment: The ARO-MAPT findings are still early-stage and were reported in healthy volunteers; they demonstrate tau knockdown and blood-brain-barrier delivery, but not yet clinical benefits for Alzheimer’s patients. Further trials will need to establish safety, efficacy, and commercial viability. Arrowhead discusses ARO-MAPT interim results and TRiM CNS delivery

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc is a biopharmaceutical company focused on developing medicines that silence disease-causing genes. Its research is based primarily on RNA interference (RNAi), a biological process that reduces the production of specific proteins by targeting messenger RNA before it can be used to make those proteins.

The company uses its proprietary Targeted RNAi Molecule (TRiM) platform to design and deliver RNAi therapeutics to selected tissues, including the liver and lungs.